← All trials
NCT03367195
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 21, 2017
- Primary completion
- Oct 31, 2018
- Completion date
- Dec 31, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 258
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Dexa Medica GroupLead sponsor
- Dr. Soetomo General HospitalOverall official - principal investigator
- Diponegoro UniversityOverall official - principal investigator
- Gadjah Mada UniversityOverall official - principal investigator
- Padjadjaran UniversityOverall official - principal investigator
- University of IndonesiaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.